The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

January 2, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In the U.S., a new formulation and an ergonomic delivery system for single doses of etanercept are now available for patients with rheumatoid arthritis (RA). In other news, the U.S. Food and Drug Administration (FDA) has approved ixekizumab to treat active psoriatic arthritis (PsA).

You Might Also Like
  • EU Approves Marketing for Ixekizumab in Adults with PsA
  • Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
Also By This Author
  • FDA Approves Lesinurad + Allopurinol

New Auto-Injector for Etanercept
In September 2017, the FDA approved the Enbrel (etanercept) Mini with AutoTouch, a new delivery system designed to administer a single dose of etanercept.1 The delivery system, which was awarded the Arthritis Foundation’s Ease of Use Commendation, is now available for patient use in the U.S .

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The AutoTouch is a reusable autoinjector for patients with RA. It features an ergonomic handle, a needle that stays hidden during injection, a skin-placement sensor, a speed switch with three injection speeds, a progress bar and a speaker.

The AutoTouch uses 50 mg/mL single-dose, prefilled cartridges of etanercept. This new etanercept formulation had significantly lower mean injection site pain than the current formulation. A Phase 3b multicenter, randomized, double-blind, crossover study in adults with moderate to severe RA or PsA was conducted to assess injection site pain associated with this modified etanercept formulation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The results: Study participants indicated they experienced a significant reduction in injection site pain. Adverse events were similar to those seen in prior studies in adults with moderate to severe RA and PsA.

FDA Approves Ixekizumab for Active PsA
In March 2016, the FDA first approved ixekizumab (Taltz) as an 80 mg/mL injection to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Recently, ixekizumab was approved to treat adults with active PsA. The agent may be administered in monotherapy or taken in combination with a conventional disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.1

The safety and efficacy of ixekizumab was established during two randomized, double-blind, placebo-controlled Phase 3 studies, SPIRIT-P1 and SPIRIT-P2, in more than 670 adults with active PsA. SPIRIT-P1 was conducted in patients with active PsA who were biologic DMARD therapy naive. SPIRIT-P2 evaluated the efficacy and safety of ixekizumab compared with placebo in tumor necrosis factor inhibitor (TNFi)-experienced patients with active PsA who failed one or two TNF inhibitors.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In both studies, patients had to have been diagnosed with active PsA for six or more months and had to have at least three tender and three swollen joints. At Week 16, inadequate responders, who were determined by blinded tender and swollen joint count criteria, received rescue therapy. These patients were then analyzed as non-responders.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: auto-injector, etanercept, ixekizumab, Psoriatic Arthritis, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • EU Approves Marketing for Ixekizumab in Adults with PsA
  • Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA
  • U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)